Tg Therapeutics (TGTX) Capital Expenditures (2012 - 2026)
Tg Therapeutics (TGTX) posted quarterly Capital Expenditures of $51000.0 for Q1 2026, up 104.0% year-over-year from $25000.0 in Q1 2025, and down 23.88% quarter-over-quarter from $67000.0 in Q4 2025.
Tg Therapeutics (TGTX) Capital Expenditures (2012 - 2026) Analysis & Trends
Tg Therapeutics' Capital Expenditures history runs 14 years deep, the most recent figure standing at $51000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 104.0% year-over-year to $51000.0; the TTM figure through Mar 2026 stood at $240000.0 (up 242.86% YoY), while the FY2025 annual figure was $214000.0, up 375.56% from the prior year.
- Capital Expenditures for Q1 2026 stood at $51000.0, down from $67000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $80000.0 in Q3 2025, with the low at $3000.0 in Q4 2022.
- The 4-year median for Capital Expenditures is $24500.0 (2024), against an average of $32400.0.
- The sharpest annual moves came in 2022 and 2025: Capital Expenditures plunged 96.25% in 2022, then surged 233.33% in 2025.
- Tg Therapeutics' Capital Expenditures stood at $3000.0 in 2022, then surged by 600.0% to $21000.0 in 2024, then jumped by 219.05% to $67000.0 in 2025, then retreated by 23.88% to $51000.0 in 2026.
- Business Quant data shows TGTX's Capital Expenditures at $51000.0 in Q1 2026, $67000.0 in Q4 2025, and $80000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 293,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 293,000.00 |
| Jun 30, 2026 | 293,000.00 |
| Mar 31, 2026 | 51,000.00 |
| Mar 31, 2026 | 51,000.00 |
| Dec 31, 2025 | 67,000.00 |
| Dec 31, 2025 | 67,000.00 |
| Sep 30, 2025 | 80,000.00 |
| Sep 30, 2025 | 80,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Dec 31, 2024 | 21,000.00 |
| Dec 31, 2024 | 21,000.00 |
| Sep 30, 2024 | 24,000.00 |
| Sep 30, 2024 | 24,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Sep 30, 2022 | 4,000.00 |